Broken String Biosciences Closes $15M Series A Funding

Broken String Biosciences, a Cambridge, UK-based genomics company building a technology platform for cell and gene therapies, raised $15M in Series A funding. As part of the round, Yoann Bonnamour, Mérieux Equity Partners, and Arnaud Autret, Illumina Ventures, join the Company’s Board of Directors. The investment also supports its ongoing growth, including recruitment for its UK team based at the Wellcome Genome Campus, Cambridge, and the establishment of a US office. Led by CEO Felix Dobbs, Broken String Biosciences provides a platform, INDUCE-seq, that enables researchers to assess the specificity of genome editing tools and evaluate the associated off-target genetic outcomes. It provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages for therapeutic targets within the genome and to advance gene editing programs.